Atara Biotherapeutics Inc (NAS:ATRA)
$ 0.6206 0.0156 (2.58%) Market Cap: 74.73 Mil Enterprise Value: 83.40 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 42/100

Atara Biotherapeutics Inc at Alliance for Regenerative Medicine Cell & Gene Meeting on the Mesa Transcript

Oct 02, 2019 / 06:15PM GMT
Release Date Price: $13.74 (+3.78%)
Unidentified Participant

And now, it's my pleasure to present Atara Biotherapeutics, and its CEO, Pascal Touchon.

Pascal Touchon
Atara Biotherapeutics, Inc. - President, CEO & Director

Morning, everybody. It's a pleasure to be here today and to be here on behalf of what we call our champions, patients with cellulose disease that we are addressing at Atara that are daily fighting against their diseases. And we call them our champions because we're here to support these champions, to find solutions for them to better fight their devastating diseases.

So I'll let you first enjoy your forward-looking statements to make sure you are all clear in your mind about what we're going to discuss in a minute. But let me summarize what we're doing at Atara in saying that we're here to build an innovative, off-the-shelf, allogeneic T cell platform that is relying on Epstein-Barr virus or EBV-specific T cells that are coming from healthy donors that then we manufacture and prepare as product. And we could, in some cases, apply next-gen CAR T technologies to these cells to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot